Literature DB >> 27303088

Drug Monographs: Ixazomib and Necitumumab.

Fern E Lawson, J Aubrey Waddell, Dominic A Solimando.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2016        PMID： 27303088      PMCID： PMC4896343          DOI： 10.1310/hpj5105-362

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  9 in total

1.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Authors:  Nick Thatcher; Fred R Hirsch; Alexander V Luft; Aleksandra Szczesna; Tudor E Ciuleanu; Mircea Dediu; Rodryg Ramlau; Rinat K Galiulin; Beatrix Bálint; György Losonczy; Andrzej Kazarnowicz; Keunchil Park; Christian Schumann; Martin Reck; Henrik Depenbrock; Shivani Nanda; Anamarija Kruljac-Letunic; Raffael Kurek; Luis Paz-Ares; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-06-01       Impact factor: 41.316

2.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Authors:  Paul G Richardson; Rachid Baz; Michael Wang; Andrzej J Jakubowiak; Jacob P Laubach; R Donald Harvey; Moshe Talpaz; Deborah Berg; Guohui Liu; Jiang Yu; Neeraj Gupta; Alessandra Di Bacco; Ai-Min Hui; Sagar Lonial
Journal:  Blood       Date:  2014-06-11       Impact factor: 22.113

3.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Authors:  Shaji K Kumar; William I Bensinger; Todd M Zimmerman; Craig B Reeder; James R Berenson; Deborah Berg; Ai-Min Hui; Neeraj Gupta; Alessandra Di Bacco; Jiang Yu; Yaping Shou; Ruben Niesvizky
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

4.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Authors:  Shaji K Kumar; Jesus G Berdeja; Ruben Niesvizky; Sagar Lonial; Jacob P Laubach; Mehdi Hamadani; A Keith Stewart; Parameswaran Hari; Vivek Roy; Robert Vescio; Jonathan L Kaufman; Deborah Berg; Eileen Liao; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Ai-Min Hui; Vincent Rajkumar; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-11-14       Impact factor: 41.316

5.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Authors:  Luis Paz-Ares; Jörg Mezger; Tudor E Ciuleanu; Jürgen R Fischer; Joachim von Pawel; Mariano Provencio; Andrzej Kazarnowicz; György Losonczy; Gilberto de Castro; Aleksandra Szczesna; Lucio Crino; Martin Reck; Rodryg Ramlau; Ernst Ulsperger; Christian Schumann; Jose Elias A Miziara; Álvaro E Lessa; Mircea Dediu; Beatrix Bálint; Henrik Depenbrock; Victoria Soldatenkova; Raffael Kurek; Fred R Hirsch; Nick Thatcher; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316

6.  A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Authors:  Bart Kuenen; Petronella O Witteveen; Rita Ruijter; Giuseppe Giaccone; Aruna Dontabhaktuni; Floyd Fox; Terry Katz; Hagop Youssoufian; Junming Zhu; Eric K Rowinsky; Emile E Voest
Journal:  Clin Cancer Res       Date:  2010-03-02       Impact factor: 12.531

7.  Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Authors:  S K Kumar; B LaPlant; V Roy; C B Reeder; M Q Lacy; M A Gertz; K Laumann; M A Thompson; T E Witzig; F K Buadi; C E Rivera; J R Mikhael; P L Bergsagel; P Kapoor; L Hwa; R Fonseca; A K Stewart; A Chanan-Khan; S V Rajkumar; A Dispenzieri
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

8.  Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.

Authors:  David C Smith; Thea Kalebic; Jeffrey R Infante; Lillian L Siu; Daniel Sullivan; Gordana Vlahovic; John S Kauh; Feng Gao; Allison J Berger; Stephen Tirrell; Neeraj Gupta; Alessandra Di Bacco; Deborah Berg; Guohui Liu; Jianchang Lin; Ai-Min Hui; John A Thompson
Journal:  Invest New Drugs       Date:  2015-03-18       Impact factor: 3.850

9.  Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.

Authors:  Neeraj Gupta; Yeow Tee Goh; Chang-Ki Min; Jae Hoon Lee; Kihyun Kim; Raymond S M Wong; Chor Sang Chim; Michael J Hanley; Huyuan Yang; Karthik Venkatakrishnan; Ai-Min Hui; Dixie-Lee Esseltine; Wee Joo Chng
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.